ENGNW — enGene Holdings Inc. Warrants
NASDAQ
$0.20
-$0.10 (-32.89%)
enGene Holdings Inc. Warrants (ENGNW) common stock listed on NASDAQ. It is led by Ronald H. W. Cooper, based in 4868 Rue Levy, Montreal, QC, Canada, H4R 2P1, with about 81 employees. enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Net income was -$79.4M.
Use this ENGNW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ENGNW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ENGNW SEC filings page. Lician reads the product cache first so this HTML stays unique to enGene Holdings Inc. Warrants even when a live quote feed is slow.
About enGene Holdings Inc. Warrants
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
ENGNW Key Statistics
Market Cap
$0.00M
Volume
55,247
Previous Close
$0.30
Day Range
$0.19 – $2.10
EPS
$1.46
Revenue
$0.00
Net Income
-$55.14M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
81
ENGNW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$55.14M | -$99.92M | -$24.46M |
| EPS (Diluted) | $1.46 | $151.22 | $44.30 |
Total Assets
$311.17M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$173.00M
Operating Cash Flow
-$48.28M
Free Cash Flow
$0.00
enGene Holdings Inc. Warrants Company Information
- President, CEO & Director
- Ronald H. W. Cooper
- Headquarters
- 4868 Rue Levy, Montreal, QC, Canada, H4R 2P1
- Website
- www.engene.com
- Phone
- 514 332 4888
- IPO / Founded
- 2023-11-01